URI accepting fellows for workshop on vaccine design for neglected tropical diseases
Todd McLeish, 401-874-7892
PROVIDENCE, R.I. – September 22, 2010 – The University of Rhode Island’s Institute for Immunology and Informatics (I’Cubed) is accepting fellows to participate in a workshop and training course in January targeting neglected tropical diseases.
Deadline for application submission is Sept. 30.
The workshop will focus on training researchers in the use of new vaccine design tools developed by URI Professor Annie De Groot and colleague Bill Martin of Epivax Inc. The workshop is funded through a $511,000 grant from the National Institutes of Health, which supplements last year’s $13 million grant for the Translational Immunology Research and Accelerated Vaccine Development program that established I’Cubed.
The training sessions will take place over three weeks in January at the URI Providence Biotechnology Center. I’Cubed will select six fellows for the training based on the applicant’s current involvement in research on neglected tropical diseases, prior doctoral or equivalent training in immunology or a related area in the vaccine development field, and substantial commitment from the applicant’s home institution to their future research career. Immunoinformatics tools will be available to the fellows after they complete the training, so that they can continue their work in the host laboratory. The tools are made available to the I’Cubed by Epivax on a non-commercial basis.
Interested researchers may apply by providing the following information:
• A description of your work, including reasons for your interests in learning to use the TRIAD toolkit and how it would apply to your research project in the future.
• A budget for your travel costs.
• Your Curriculum Vitae (NIH formatted).
• Two letters of reference.
Application materials should be sent electronically to Shahla Yekta at email@example.com. For more information about De Groot, the Institute for Immunology and Informatics, and the TRIAD grant research, visit www.immunome.org.